NSCLC Clinical Trials in Guangzhou, Guangdong
28 recruitingGuangzhou, Guangdong, China
Showing 1–20 of 28 trials
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled207 locationsNCT06422143
Recruiting
Phase 3
IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed
iO Resistant sqNSCLC
Fortvita Biologics (USA)Inc.600 enrolled44 locationsNCT07217301
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC556 enrolled194 locationsNCT06074588
Recruiting
Phase 3
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Non-small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.180 enrolled29 locationsNCT07154706
Recruiting
Phase 2
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
Lung Cancer (NSCLC)
Sun Yat-sen University56 enrolled1 locationNCT07103395
Recruiting
Phase 2
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
MRDNSCLC (Non-small Cell Lung Cancer)II-IIIB Stages+1 more
Guangdong Association of Clinical Trials115 enrolled2 locationsNCT07120698
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 2
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
Stage IB-IIIB NSCLCStage IIB-III NSCLC
Wen-zhao ZHONG211 enrolled1 locationNCT07039656
Recruiting
Phase 2
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）
Lung Cancer (NSCLC)
Sun Yat-sen University32 enrolled1 locationNCT06924398
Recruiting
Phase 3
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
NSCLC (Non-small Cell Lung Cancer)
Guangdong Provincial People's Hospital70 enrolled1 locationNCT07016126
Recruiting
Phase 3
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
Lung Cancer (NSCLC)
Yang Hong360 enrolled1 locationNCT06598527
Recruiting
Phase 2
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
Non-small Cell Lung Cancer (NSCLC)
Sun Yat-sen University83 enrolled1 locationNCT06977074
Recruiting
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
Lung CancerLung Cancer (NSCLC)Lung+1 more
The First Affiliated Hospital of Guangzhou Medical University2,500 enrolled1 locationNCT06843707
Recruiting
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
Lung Cancer (NSCLC)
Guangdong Provincial People's Hospital120 enrolled1 locationNCT06771960
Recruiting
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
Lung CancerCancerNSCLC+1 more
The First Affiliated Hospital of Guangzhou Medical University2,500 enrolled1 locationNCT06778512
Recruiting
Phase 2
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
Non-small Cell Lung Cancer (NSCLC)Leptomeningeal MetastasesBrain Metastases+2 more
Li-kun Chen70 enrolled1 locationNCT06728865
Recruiting
Phase 1Phase 2
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.354 enrolled1 locationNCT05435248
Recruiting
Not Applicable
Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer
NSCLC
Energenx Medical LTD.10 enrolled1 locationNCT05987345
Recruiting
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University1,000 enrolled1 locationNCT01994057